3-(4-phenylbutylamino)propanol | 847259-95-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-phenylbutylamino)propanol
• 英文别名: 3-(4-Phenylbutylamino)propan-1-ol
• CAS: 847259-95-4
• 化学式: C₁₃H₂₁NO
• 分子量: 207.316
• InChiKey: MAKHDLIPEAWTEC-UHFFFAOYSA-N

物化性质

• 沸点：
  345.0±35.0 °C(Predicted)
• 密度：
  0.982±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4-phenylbutylamino)propanol 在 4-二甲氨基吡啶 作用下， 以 甲醇 、 三氟甲磺酸 、 叔丁醇 为溶剂， 反应 27.0h， 生成 1-hydroxyimino-3-(3-hydroxypropyl)-4,5,6,7-tetrahydro-3-benzazonin-2-one triflate
  参考文献：
  名称：

  硝基乙酰胺衍生物在三氟甲磺酸中的环化反应

  摘要：

  N-(3-羟丙基)-2-硝基-N-(ω-苯基烷基)乙酰胺在三氟甲磺酸中进行分子内环化，得到相应的羟基亚氨基六至九元苯并稠合内酰胺。六元衍生物慢慢转化为 2-(3-羟丙基)isoquinolin-3-one。核磁共振原位光谱分析提供了有关反应中涉及的阳离子物质的信息，从而可以假设一种机制。该反应为苯并稠合内酰胺提供了一种新颖且简单的途径。

  DOI：

  10.1055/s-0033-1340960
• 作为产物：
  描述：

  4-苯基-1-丁基溴 、 3-氨基-1-丙醇 以 甲醇 为溶剂， 反应 72.0h， 生成 3-(4-phenylbutylamino)propanol
  参考文献：
  名称：

  硝基乙酰胺衍生物在三氟甲磺酸中的环化反应

  摘要：

  N-(3-羟丙基)-2-硝基-N-(ω-苯基烷基)乙酰胺在三氟甲磺酸中进行分子内环化，得到相应的羟基亚氨基六至九元苯并稠合内酰胺。六元衍生物慢慢转化为 2-(3-羟丙基)isoquinolin-3-one。核磁共振原位光谱分析提供了有关反应中涉及的阳离子物质的信息，从而可以假设一种机制。该反应为苯并稠合内酰胺提供了一种新颖且简单的途径。

  DOI：

  10.1055/s-0033-1340960

文献信息

• NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1661904A1

  公开（公告）日：2006-05-31

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar-B- group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R5, R6, R7, and R8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar-B'- group (B' is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an -NR4- group (R4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R4' is hydrogen atom, or a group represented by the aforementioned formula (a) (R3" and R4" represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  由以下一般式（1）表示的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[R1为氢原子，或线性C1-6烷基羰基基团；R2为氢原子，或C1-6烷基羰基基团；R3为氢原子，C1-6烷基基团，C1-6烷基羰基基团，C1-6烯基基团，C2-6烯基羰基基团，C2-6炔基基团，或Ar-B-基团（Ar表示芳基团，或杂环基团，B为C1-6烷基基团，C1-6烷基羰基基团，C2-6烯基基团，C2-6烯基羰基基团，或C2-6炔基基团）；R5、R6、R7和R8表示氢原子，C1-6烷基基团，C2-6烯基基团，C2-6炔基基团，或Ar-B'-基团（B'为C1-6烷基基团，C2-6烯基基团，或C2-6炔基基团）；X为氧原子，或一个-NR4-基团（R4为氢原子，C1-6烷基基团，或C1-6烷基基团，可能被芳基取代）；R4'为氢原子，或由上述式（a）表示的基团（R3"和R4"表示氢原子，或线性或支链状C1-6烷基羰基基团）]
• Novel azalides derived from 16-membered macrolides. Part II: Isolation of the linear 9-formylcarboxylic acid and its sequential macrocyclization with an amino alcohol or an azidoamine
  作者：Tomoaki Miura、Kenichi Kanemoto、Satomi Natsume、Kunio Atsumi、Hideki Fushimi、Takuji Yoshida、Keiichi Ajito

  DOI：10.1016/j.bmc.2008.09.054

  日期：2008.12

  followed by macrolactam formation with an amine generated from the azide gave 14- to 16-membered azalactams. Among these derivatives, 15-membered azalactams and 16-membered azalides exhibited characteristic in vitro antibacterial activities. Although optimization of 15-membered azalactams including demycarosyl analogues did not provide remarkably promising molecules, SAR studies of 16-membered azalides disclosed

  报道了从16元大环内酯类化合物开始的新型14至16元11-氮杂叠氮化物的设计和合成。通过先前报道的移动二醛分离线性9-甲酰基羧酸。用氨基醇对甲酰基羧酸进行顺序大环化，然后脱保护，得到相应的14至16元氮杂内酯。另一方面，用叠氮基胺对甲酰基羧酸进行还原胺化，然后用由叠氮化物生成的胺形成大内酰胺，得到14至16元的氮杂内酰胺。在这些衍生物中，15元氮杂内酰胺和16元氮杂内酯类药物表现出特征性的体外抗菌活性。尽管优化包括脱麦芽糖基类似物的15元氮杂内酰胺不能提供非常有前途的分子，
• Nozel azalide and azalactam derivatives and method for producing the same
  申请人：Miura Tomoaki

  公开号：US20070042974A1

  公开（公告）日：2007-02-22

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R 1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R 2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R 3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar—B— group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar—B′— group (B′ is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an —NR 4 — group (R 4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R 4′ is hydrogen atom, or a group represented by the aforementioned formula (a) (R 3″ and R 4″ represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  下列通式（1）所代表的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[其中R1为氢原子或线性C1-6烷基羰基基团；R2为氢原子或C1-6烷基羰基基团；R3为氢原子、C1-6烷基、C1-6烷基羰基基团、C1-6烯基、C2-6烯基羰基基团、C2-6炔基或Ar-B-基团（Ar代表芳基或杂环基，B为C1-6烷基、C1-6烷基羰基基团、C2-6烯基、C2-6烯基羰基基团或C2-6炔基）；R5、R6、R7和R8代表氢原子、C1-6烷基、C2-6烯基、C2-6炔基或Ar-B′-基团（B′为C1-6烷基、C2-6烯基或C2-6炔基）；X为氧原子或-NR4-基团（R4为氢原子、C1-6烷基或可被芳基取代的C1-6烷基）；R4′为氢原子或上述通式（a）所代表的基团（R3″和R4″代表氢原子或线性或支链状C1-6烷基羰基基团）]
• HCV NS3 PROTEASE INHIBITORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20140296136A1

  公开（公告）日：2014-10-02

  The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

  本发明涉及公式（I）的大环化合物，它们是丙型肝炎病毒（HCV）NS3蛋白酶的抑制剂，它们的合成以及它们用于治疗或预防HCV感染的用途。
• US7365174B2
  申请人：——

  公开号：US7365174B2

  公开（公告）日：2008-04-29